Coccidiosis, caused by intracellular protozoan parasites of the genus Eimeria, poses severe threats to poultry production by compromising intestinal health, reducing feed efficiency, and increasing mortality rates. The disease results in substantial economic losses worldwide, estimated in the billions annually, due to decreased productivity and the costs associated with treatment and prevention. Traditional vaccines against coccidiosis have struggled with issues such as incomplete protection, complicated administration, and the emergence of drug-resistant Eimeria strains, driving the urgent need for innovative solutions with enhanced efficacy and safety profiles.

Addressing these challenges, the research team focused on harnessing the natural immune system stimulation capabilities of Salmonella Enteritidis, a bacterium already known for its role as a live attenuated vaccine vector in various veterinary and human applications. By engineering this bacterium to express the EnGAM59 antigen encoded from Eimeria necatrix, the scientists sought to prime the host’s immune system to recognize and combat the parasite more effectively. This approach capitalizes on Salmonella’s ability to invade mucosal tissues, thereby eliciting robust mucosal and systemic immunity crucial for warding off intestinal pathogens.

The construction of the recombinant Salmonella vaccine involved meticulous molecular biology techniques, including gene cloning, plasmid insertion, and attenuation of bacterial virulence to ensure safety without compromising immunogenicity. The EnGAM59 antigen, specifically expressed during Eimeria necatrix gametocyte development, was chosen due to its potential role in interrupting the parasite’s life cycle within the host. Through this targeted expression, the vaccine aims to induce immune responses that limit gametocyte formation, thereby reducing oocyst shedding and subsequent transmission.

Extensive in vivo evaluations were conducted on broiler chickens to determine the vaccine’s protective efficacy and immunological responses. Vaccinated birds displayed markedly reduced intestinal lesion scores and oocyst output compared to controls, indicating robust protective immunity against Eimeria necatrix challenge. Moreover, performance parameters such as body weight gain and feed conversion ratios improved significantly in vaccinated groups, demonstrating tangible benefits in poultry production metrics. These findings underscore the vaccine’s dual role in disease mitigation and productivity enhancement.

Immunological assays revealed elevated levels of antigen-specific antibodies and heightened activation of cellular immunity, characterized by increased proliferation of T-lymphocytes and secretion of protective cytokines. This comprehensive immune activation is particularly noteworthy, as it addresses the multifaceted nature of protective immunity required to combat coccidiosis, which involves both humoral and cell-mediated mechanisms. The vaccine’s ability to induce mucosal immunity is especially critical given the intestinal tropism of Eimeria parasites.

Another pivotal advantage of the recombinant Salmonella vaccine lies in its delivery route and administration simplicity. Oral vaccination mimics natural infection pathways, stimulating mucosal defenses while facilitating large-scale immunizations without the need for injections. This ease of administration presents significant logistical benefits for poultry producers, enabling cost-effective and stress-free vaccination protocols suitable for commercial operations. The attenuated nature of the vaccine strain also contributes to its safety, minimizing risks associated with live vaccines.

The innovative use of a recombinant bacterial vector in the context of parasitic disease control marks a paradigm shift in veterinary vaccinology. Previously, most coccidiosis vaccines relied on live parasite formulations, which carry inherent risks of residual pathogenicity and require careful handling. By contrast, recombinant vector vaccines offer precise antigen delivery, reduced side effects, and potential for multivalent vaccine development incorporating multiple parasitic antigens. This flexibility could address the complex infections involving multiple Eimeria species common in poultry farms.

Further genetic and immunological analyses cemented the vaccine strain’s stability and expression fidelity, ensuring consistent antigen presentation across production batches. This quality control is essential for regulatory approval and widespread adoption. The research also highlighted the vaccine’s potential to limit environmental contamination by reducing oocyst shedding, thereby improving biosecurity measures at the farm level and decreasing the reliance on anticoccidial drugs that often contribute to resistance development.

Beyond poultry, the study’s implications extend to broader fields of infectious disease control. The tailored use of bacterial vectors to deliver protozoan parasite antigens could inspire analogous vaccine strategies targeting other intracellular pathogens affecting both animals and humans. Such cross-disciplinary applications demonstrate the versatility and transformative potential of recombinant microbial vaccines in modern medicine and agriculture.

Looking ahead, the research team aims to optimize vaccine dosing regimens, explore long-term immunity durations, and evaluate cross-protection against other Eimeria species. Integration with existing coccidiosis control programs, including management and nutrition, will be key to maximizing the vaccine’s impact. Field trials in commercial poultry settings are anticipated to confirm efficacy under diverse environmental conditions, further supporting regulatory approvals and eventual market release.

The economic and social repercussions of this vaccine development cannot be overstated. By providing a safer, more effective, and user-friendly solution for coccidiosis control, the innovation promises to enhance global food security, promote animal welfare, and reduce environmental hazards linked to chemical treatments. Poultry farmers, particularly in developing regions where coccidiosis inflicts severe losses, stand to benefit tremendously, potentially transforming livelihoods and strengthening local economies.

This landmark study exemplifies the power of interdisciplinary collaboration, marrying microbiology, immunology, and parasitology to tackle a persistent global challenge. It reflects the accelerating trend towards precision livestock medicine, leveraging genetic engineering and molecular technologies to foster sustainable agricultural practices. As the poultry industry grapples with increasing demands and disease pressures, such advances in vaccine science offer a beacon of hope.

In summary, the recombinant attenuated Salmonella Enteritidis vaccine expressing the EnGAM59 antigen represents a monumental leap forward in the fight against coccidiosis. With comprehensive experimental validation and a strong foundation in molecular design, this vaccine heralds a new era of parasitic disease management marked by enhanced protection, safety, and practicality. Its deployment could redefine poultry health paradigms and inspire continued innovation in the quest for effective, sustainable disease interventions worldwide.

Subject of Research: Development of a recombinant attenuated Salmonella Enteritidis vaccine expressing the EnGAM59 gametocyte antigen from Eimeria necatrix for controlling coccidiosis in poultry.

Article Title: Development and Evaluation of a Recombinant Attenuated Salmonella Enteritidis Vaccine Expressing the EnGAM59 Gametocyte Antigen of Eimeria necatrix for Coccidiosis Control.

Article References:
Liu, D., Feng, Y., Zhang, Y. et al. Development and Evaluation of a Recombinant Attenuated Salmonella Enteritidis Vaccine Expressing the EnGAM59 Gametocyte Antigen of Eimeria necatrix for Coccidiosis Control. Acta Parasit. 70, 160 (2025). https://doi.org/10.1007/s11686-025-01100-4

Image Credits: AI Generated

In a groundbreaking study, the laboratory of Professor Jan Terje Andersen has unveiled a novel vaccine technology platform that ingeniously fuses a subunit antigen to albumin. Albumin, a protein abundant in human serum, was selected due to its natural capability to be actively transported across mucosal barriers via the neonatal Fc receptor (FcRn), located on mucosal epithelial cells. This innovative approach aims to create vaccines that not only elicit a systemic immune response but also stimulate a robust mucosal immune response directly where respiratory pathogens enter the body.

The implications of this research are profound, as the potential for an effective means of vaccination against respiratory viral infections could reduce the frequency and severity of outbreaks. In preclinical studies conducted on various mouse strains, researchers demonstrated that the albumin-antigen fusion vaccines, delivered intranasally, prompted significant systemic and mucosal antibody responses. Notably, the mice exhibited considerable protection against viral challenges, such as those posed by SARS-CoV-2 and influenza A, underscoring the promise of this new vaccine platform.

One of the distinguishing features of this study is the strategic incorporation of adjuvants, which can enhance the immune response elicited by vaccines. In the novel albumin-based vaccine approach, these adjuvants were site-specifically conjugated to the albumin carrier, thereby allowing for an optimized immune response at the mucosal sites. This targeted approach is essential because the most effective vaccines are those that can induce high levels of immunoglobulin A (IgA) antibodies in the mucosal tissues, which play a critical role in neutralizing pathogens at the site of invasion.

Intriguingly, when comparing the new albumin-based vaccine strategy to established vaccine platforms, such as an intramuscularly administered mRNA vaccine or an intranasally delivered antigen fused to a protein carrier of similar size to albumin, only the albumin-based formulation led to robust mucosal IgA antibody responses. This finding highlights the unique advantages of using albumin as a carrier in vaccine design, making it a compelling candidate for future vaccine development targeting respiratory pathogens.

Professor Jan Terje Andersen, the senior author of the study, emphasized the critical need for improved vaccines against respiratory pathogens that are responsible for high mortality rates. His enthusiastic endorsement of the new vaccine technology reflects the potential it holds not only for immediate applications but also for future vaccine design. The albumin-based platform is adaptable, allowing for the antigen to be any identified protein subunit derived from infectious agents.

The engineering of a human albumin variant with an enhanced ability to engage FcRn paves the way for more effective antigen transport across mucosal barriers. This means that, following transport, the immune system can be primed to recognize and respond to the vaccine subunit effectively. The in-depth exploration of FcRn interactions and binding nuances across species has been vital to ensure that this vaccine technology is translatable and relevant across different biological contexts.

As the global community witnesses an increased frequency of respiratory viruses, the relevance of this research cannot be overstated. With the ongoing threat of pandemics, innovative vaccine technologies that respond to emerging infectious diseases are of utmost importance. The careful consideration of cross-species differences in immune responses further enhances the translational potential of this research, making it a promising contender in the race to develop effective vaccines for current and future viral outbreaks.

Moreover, the funding and support for this study, provided by organizations such as the Research Council of Norway, the South-Eastern Norway Regional Health Authority, the Coalition for Epidemic Preparedness and Innovation (CEPI), and Independent Research Fund Denmark, underscore the collaborative effort required to address these pressing public health challenges.

As scientists continue to refine and expand upon this vaccine platform, it is essential to engage in further research that explores its efficacy against a wider array of respiratory pathogens. The potential to develop a vaccine that can efficiently elicit a robust immune response at mucosal surfaces could revolutionize the way we approach the prevention of respiratory illnesses. Continued investigation into the nuances of immune responses elicited by the albumin-based vaccines will provide deeper insights and further establish its place in future vaccine design.

In conclusion, the findings from Professor Andersen and his team mark a significant advancement in vaccine research and open new avenues for the development of effective vaccines against respiratory pathogens. Their innovative albumin-based vaccine technology platform represents a remarkable stride towards achieving protection at the very locations where infections initiate. As the scientific community moves forward, this work lays a strong foundation for future endeavors aimed at enhancing the efficacy of vaccines in combating the next wave of viral threats facing global health.

Subject of Research: Novel vaccine technology for respiratory pathogens
Article Title: An intranasal subunit vaccine induces protective systemic and mucosal antibody immunity against respiratory viruses in mouse models
News Publication Date: 1-May-2025
Web References: https://doi.org/10.1038/s41467-025-59353-6
References: Available upon request
Image Credits: N/A

Keywords

Vaccine, mucosal immunity, respiratory pathogens, albumin, FcRn, COVID-19, influenza, antibody responses, vaccine technology, immunology, translational research.

Central to this innovative vaccine’s success is its ability to precisely incorporate two pivotal viral proteins: hemagglutinin (H5) and neuraminidase (N1). These proteins are integral to the virus’s infectious cycle, with hemagglutinin facilitating viral entry into host cells, while neuraminidase plays a crucial role in the release and spread of new viral particles. Unlike many existing vaccines that primarily target the hemagglutinin protein, this platform explores a bivalent approach, combining immune targets to potentially enhance protection and broaden the vaccine’s efficacy against viral mutations.

The platform leverages recombinant protein technology, eschewing traditional egg-based vaccine production methods. Instead, the H5 and N1 proteins are engineered with a histidine tag—a short amino acid sequence with a natural affinity for metals—that allows them to bind efficiently and specifically to cobalt ions embedded within cobalt-porphyrin-phospholipid (CoPoP) nanoparticles. This nanoparticle scaffold forms the core of the vaccine delivery system, providing a stable and versatile platform that presents antigens in a manner that effectively stimulates the immune system.

Preclinical trials conducted on mice exhibited compelling results: administration of hemagglutinin alone conferred full protection, completely preventing signs of illness, weight reduction, and viral replication within lung tissues. The neuraminidase-only formulation, while providing partial immunity with approximately 70% effectiveness, demonstrated the capacity to reduce viral load and disease severity, underscoring the importance of neuraminidase antibodies in modulating infection. Interestingly, the combination of H5 and N1 as a bivalent vaccine did not surpass the efficacy observed with hemagglutinin alone, suggesting a predominant role for hemagglutinin in protective immunity but reaffirming the supportive benefits of neuraminidase-targeted responses.

The CoPoP nanoparticle’s design not only supports antigen presentation but also incorporates potent adjuvants—including QS-21, a saponin derivative known to enhance cellular and humoral immune responses, and PHAD, a synthetic monophosphoryl lipid A derivative acting as a Toll-like receptor 4 agonist. Both adjuvants are embedded within the phospholipid bilayer shell, amplifying the vaccine’s immunogenicity by promoting a robust and durable immune activation. This molecular synergy enables the platform to elicit broad-spectrum protection with potentially improved durability and response quality compared to conventional vaccines.

What distinctly sets this vaccine platform apart is its manufacturing advantage. Traditional influenza vaccines rely heavily on egg-based propagation of live or attenuated viruses—a time-consuming process susceptible to supply chain constraints. In contrast, the UB strategy produces antigenic proteins through recombinant expression systems, which are then effortlessly conjugated to nanoparticles via rapid and stable metal-affinity interactions. This method promises expedited vaccine production timelines, scalability, and adaptability critical in responding swiftly to emergent virus strains during pandemics or zoonotic spillovers.

The CoPoP nanoparticle technology underlying this vaccine platform is not a nascent concept; it has undergone advanced clinical evaluations in unrelated viral contexts, notably as a COVID-19 vaccine candidate. These phase 2 and 3 trials, conducted in collaboration with industry partners and international research bodies, have demonstrated the platform’s safety and immunogenic profile in humans, bolstering confidence that the technology can be effectively translated into licensed vaccines for other pathogens, including avian influenza.

From a molecular perspective, the strategic use of histidine-tagged antigens exploits the affinity between imidazole side chains of histidine residues and transition metal ions, fostering swift and stable antigen attachment without compromising protein conformation or function. This design ensures that the antigens display native epitopes essential for inducing neutralizing antibodies and T-cell responses, a feat difficult to achieve in many subunit vaccine approaches.

Moreover, the research highlights the nuanced roles of viral glycoproteins in immune defense. Hemagglutinin serves as the viral key for host cell interaction, dictating entry specificity and initial infection, which makes it a prime neutralizing antibody target. Neuraminidase, acting as an enzymatic scissors, cleaves sialic acid residues to facilitate virion release, and while antibodies targeting N1 are non-neutralizing in the classical sense, they reduce viral dissemination and disease severity, contributing to overall vaccine efficacy. This understanding of immunological mechanisms reinforces the rationale for including multiple antigenic components to counteract viral escape mutations.

Looking ahead, the UB team intends to expand their evaluations by experimenting with dosage variations, vaccination schedules, and administration routes to optimize the vaccine’s protective effect and practical deployment. The multi-institution collaboration, spanning public health agencies, national microbiology laboratories, veterinary research centers, and biotech firms, exemplifies the integrative approach necessary to combat complex zoonotic threats effectively.

The promise of this vaccine platform extends beyond avian influenza. Its modular design, speed of production, and potent immune activation could serve as a blueprint for rapid response vaccines against other emerging infectious diseases. In an era marked by the continuous emergence of viral variants with pandemic potential, innovative technologies such as this herald a new paradigm in vaccinology, where precision engineering, nanotechnology, and immunology converge to safeguard both animal and human health.

The research, slated for publication in the prestigious journal Cell Biomaterials, epitomizes cutting-edge advances that could redefine influenza vaccination frameworks and fortify global preparedness against evolving viral pathogens.

Subject of Research: Avian influenza vaccine development targeting H5N1 variant 2.3.4.4b using a cobalt-porphyrin-phospholipid nanoparticle platform.

Article Title: University at Buffalo Develops Novel Nanoparticle Platform Achieving Complete Protection Against Deadly H5N1 Avian Influenza Variant in Mice

News Publication Date: 17-Apr-2025

Image Credits: University at Buffalo

Keywords: Avian influenza, Flu vaccines, Animal research, Influenza viruses, Bond formation, Vaccine development, Wild birds, Public health, COVID 19, Recombinant proteins, Cell division, Animal models